☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Oral Shift
Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #...
June 13, 2019
Load more...
Back to Home